Expression of TRAIL receptors and cFLIP correlates with grade of malignancy and survival in patients with hepatocellular carcinoma
S Brost, T Longerich, U Hinz, R Koschny, J Sykora, E Batke, K Breuhahn, P Schemmer, H Walczak, W Stremmel, P Schirmacher, TM Ganten · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Bibliografische Angaben
Zusammenfassung
BACKGROUND AND Aims: TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis upon binding to TRAIL death receptors TRAIL receptor 1 (TRAIL-R1) and TRAIL-R2. TRAIL-R3 and TRAIL-R4 have no or only a truncated death domain and cannot induce apoptosis. On the contrary, activation of TRAIL-R4 might promote cell survival and proliferation. cFLIP is a potent inhibitor of the extrinsic apoptosis pathway. The anti-tumor activity of TRAIL-R1 and TRAIL-R2 agonists is currently investigated in clinical trials. Recent studies have demonstrated that TRAIL receptor and cFLIP expression is altered in HCC. Therefore we a…
